Ken Takeshita, Kite global head of clinical development (Gilead)

Gilead’s Kite snares a land­mark FDA OK on a $373,000 CAR-T ther­a­py — which comes with brag­ging rights to the first true fran­chise op

While many of the top play­ers in the im­muno-on­col­o­gy field have shift­ed their fo­cus to new and bet­ter CAR-Ts in the pipeline, one of the pi­o­neers in the field is now proud­ly lay­ing claim to a land­mark achieve­ment — gain­ing a sec­ond OK and cre­at­ing the first com­mer­cial CAR-T port­fo­lio.

“We’re about to be­come the first com­pa­ny with a cell ther­a­py fran­chise,” says Ken Takeshi­ta, head of glob­al de­vel­op­ment at Kite Ther­a­peu­tics, a sub­sidiary of Gilead. The drug will be mar­ket­ed as Tecar­tus and sold for $373,000, ac­cord­ing to a com­pa­ny spokesper­son on Fri­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.